Physician profile

Tejinder S Mander

Cardiovascular Disease · Greenville, MI

NPI 1740265701

$15,067.80

in general payments reported to CMS, 2019-2025

53 companies · $2,314 in 2025

The $2,314 reported for 2025 was more than what 85% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$6,166.24
Education$115.21

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Amgen INC. $1,490.13 2019-2025 Repatha, Repatha
Shockwave Medical, INC $1,380.62 2021-2025 Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter
Janssen Pharmaceuticals, INC $1,333.06 2019-2024 Xarelto
Novartis Pharmaceuticals Corporation $1,158.00 2019-2025
Astrazeneca Pharmaceuticals LP $1,032.37 2019-2025 Brilinta, Andexxa, Farxiga
E.R. Squibb & Sons, L.L.C. $860.61 2019-2025 Camzyos, Eliquis
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $673.99 2019-2025 Lifevest
Bayer Healthcare Pharmaceuticals INC. $650.36 2021-2025
Amarin Pharma, INC. $629.08 2019-2022
Pfizer INC. $596.89 2019-2025
Boehringer Ingelheim Pharmaceuticals, INC. $544.86 2019-2025 Jardiance
Merck Sharp & Dohme LLC $493.74 2021-2025 Verquvo, Winrevair
Actelion Pharmaceuticals US, INC. $431.60 2021-2025 Opsumit, Uptravi
Alnylam Pharmaceuticals INC. $420.17 2022-2025 Onpattro, Amvuttra
Boston Scientific Corporation $398.82 2019-2025 General - Therapies, Avvigo Guidance System, Rotapro
Show all 53 companies
CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $387.82 2019-2025 Wegovy, Rybelsus, Ozempic
Abbott Laboratories $321.03 2019-2024 Cardiomems
Chiesi USA, INC. $212.79 2019-2025 Cleviprex, Kengreal
Kiniksa Pharmaceuticals, LTD. $210.53 2021-2023 Arcalyst
Daiichi Sankyo INC. $167.02 2019-2024 Injectafer
Esperion Therapeutics, INC. $166.67 2020-2025 Nexletol
Astellas Pharma US INC $120.02 2021
Irhythm Technologies, INC. $100.85 2019-2022
Sanofi-Aventis U.S. LLC $99.13 2019-2023
Lundbeck LLC $95.04 2019-2021
Kiniksa Pharmaceuticals International, Plc $93.03 2024 Arcalyst
Csl Behring $89.60 2022
Regeneron Healthcare Solutions, INC. $81.59 2019
Vital Connect, INC $66.26 2024 Vitalpatch Rtm
Bridgebio Pharma, INC. $62.91 2025 Attruby
Bardy Diagnostics, INC. $60.01 2021-2022
Kowa Pharmaceuticals America, INC. $53.60 2020-2023 Livalo
Lilly USA, LLC $47.88 2025 Zepbound, Mounjaro
Xeris Pharmaceuticals, INC. $45.15 2025 Keveyis
Hologic INC $44.40 2022
Medtronic Vascular, INC. $39.93 2020
Impulse Dynamics (USA) INC. $39.21 2023-2024 Optimizer, Optimizer
Atricure, INC. $38.79 2022
Janssen Biotech, INC. $34.00 2019
Baxter Healthcare $32.45 2024 Hillrom - Cardiac Ambulatory Monitor
Lexicon Pharmaceuticals, INC. $30.31 2023 Inpefa
Dexcom, INC. $29.01 2025 Dexcom G6 Transmitter
Kestra Medical Technology Services, INC. $28.14 2024 Assure Wcd
Alexion Pharmaceuticals, INC. $23.07 2021
Biotronik INC. $20.99 2025
Abiomed $20.58 2025
Elutia, INC. $20.16 2021
Genzyme Corporation $19.13 2025
Amryt Pharma Holdings LTD $16.88 2021
Scpharmaceuticals INC. $15.07 2025
Medtronic USA, INC. $14.13 2020
Bsn Medical INC $13.38 2020
Philips North America LLC $12.94 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Tejinder S Mander

$15,067.80

in general payments reported 2019-2025

Years
2019-2025
Top company
Amgen INC.
Context
The $2,314 reported for 2025 was more than what 85% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/78607/tejinder-s-mander

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.